Artios Pharma lands £90m Series D led by SV Health Investors and RA Capital Management to advance DNA damage response therapeutics

Artios Pharma, a biopharmaceutical company committed to realising the therapeutic power of targeting the DNA damage response in cancer, today announced the successful close of an oversubscribed £90 million Series D financing. The round was co-led by founding investor SV Health Investors and new investor RA Capital Management, with participation from new investor Janus Henderson Investors and broad support from Artios’ existing investors.

The Series D proceeds will expand the clinical evaluation of Artios’ lead programme, alnodesertib, to enrol additional ATM-negative1 patients in each of second-line pancreatic cancer and third-line colorectal cancer, for which the programme was recently granted U.S. FDA Fast Track Designation.

At the AACR meeting in April 2025, Artios reported that alnodesertib, in combination with low-dose irinotecan, demonstrated a 50% confirmed overall response rate in patients with ATM-negative solid tumours at the recommended Phase 2 dose in the STELLA Phase 1/2a trial.

There are currently no approved therapies specifically for patients whose tumours harbour ATM-deficiency, a population where alnodesertib has demonstrated durable responses across eight different solid tumours.

The proceeds from the financing will also be used to initiate a Phase 2 randomised clinical trial for Artios’ second potential first-in-class candidate, ART6043, in patients with BRCA-mutant HER2-negative breast cancer who are eligible to receive a PARP inhibitor. The DNA polymerase Theta (Polθ) inhibitor, ART6043, demonstrated an attractive tolerability profile, expected PK/PD activity, and promising clinical signals in data from a Phase 1/2a study presented at the ESMO Congress in September 2025.

The company is also advancing a first-in-class and highly differentiated DDR inhibitor Antibody Drug Conjugate (DDRi-ADC) programme and expects to name a lead candidate in Q1 2026.

This Series D accelerates our potential path to registration for both alnodesertib and ART6043, broadening development for the next generation of DNA damage response (DDR) therapeutics to indications among the highest of unmet need across pancreatic, colorectal, and breast cancers, where median survival is often measured in months, As we address these indications and prepare for others, I would like to thank our existing investors, led by SV Health, for their ongoing support, and also our new investors, RA Capital Management and Janus Henderson Investors, for joining our mission to bring these potential medicines to patients as quickly as possible.

Mike Andriole, CEO

We are thrilled to have supported Artios’ evolution, from an early-stage DDR pioneer when we founded the company to the established company it has become, distinguished by a promising and differentiated pipeline. We look forward to continuing to do so as it deploys the Series D proceeds to drive late-stage development of alnodesertib as well as its pipeline. This financing, and the recent appointment of Mike Andriole as CEO, are exciting steps in Artios’ continued growth and its transition toward becoming a commercially oriented organisation.

Nikola Trbovic, Partner at SV Health Investors

We are excited to co-lead this financing round to advance the next generation of DNA damage response therapeutics. Artios' differentiated clinical programmes, alnodesertib and ART6043, together have the potential to meaningfully expand the impact of DDR-targeted therapies. The rate and durability of responses observed to date for alnodesertib across a range of solid tumours and the early clinical results with ART6043 underscore the strength of Artios' approach and ability to deliver novel, potentially first-in-class treatments for patients while building significant long-term value.

Jake Simson, Partner at RA Capital Management

🔗